Personalising AML treatment: beyond age and fitness The Lancet Haematology (+... ++)

Personalising AML treatment: beyond age and fitness The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol13no10/PIIS2352-3026(26)X2009-9 High time for risk-adapted treatment in mantle cell lymphoma Prof Ingrid Glimelius, PhDa Send email to ingrid.glimelius@igp.uu.se ∙ Anna Nikkarinen, PhDa ∙ Leo Meriranta, PhDb ∙ Simon Husby, PhDc,d ∙ Prof Christiane Pott, PhD https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00127-4/abstract?dgcid=raven_jbs_etoc_feature_lanhae Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial Alina Markova, MDa,c Send email to markovaa@mskcc.org ∙ Jelena Ostojić, PhDe,f ∙ Veronica Rotemberg, MD PhDa ∙ Ian Nykaza, BSa,c ∙ Jad Kanbar, PhDf ∙ Esperanza B Papadopoulos, MDb,c ∙ et al. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00201-2/fulltext?dgcid=raven_jbs_etoc_feature_lanhae